WuXi Biologics (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), announced its sixth consecutive inclusion in the FTSE4Good Index Series. This honor recognizes the company's strong sustainability achievements and highlights its ongoing leadership in Environmental, Social and Governance practices along with its skill in generating value for worldwide partners through Green CRDMO solutions.

The FTSE4Good Index Series, introduced in 2001 by FTSE Russell (part of the London Stock Exchange Group), tracks equity performance of firms with robust ESG records. It acts as a guide for investors focused on sustainability targets. This year WuXi Biologics placed in the top 4 percent of the global health care sector for ESG results and showed strong outcomes in corporate governance, ethics, labor standards, environmental oversight, and sustainability planning.

As a worldwide leader in Green CRDMO solutions for biologics, WuXi Biologics weaves sustainability into operations management, technology advances, and supply chain processes. These steps help global partners boost research and development plus operational efficiency, lower product carbon footprints and lifecycle environmental effects, and meet growing sustainable procurement demands across markets.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, stated, "We are pleased to earn inclusion in the FTSE4Good Index Series for the sixth year in a row. This distinction reflects the advances WuXi Biologics has achieved in high-standard ESG practices and strengthens our dedication to embedding sustainability into long-term business expansion. We will keep advancing our Green CRDMO strategy and work with global partners to build sustainability strengths through green, innovative, and high-quality biologics solutions, generating lasting value together."

Over the years WuXi Biologics has earned consistent praise for sustainable development from major global ESG rating agencies. These include MSCI AAA Ratings, EcoVadis Platinum Medal, placement in Dow Jones Best-in-Class World Index and Emerging Markets Index, A List status from CDP for Climate Change, Water Security, and Supplier Engagement Assessment, the top negligible-risk rating by Morningstar Sustainalytics plus designation as a Sustainalytics industry and regional ESG Leader, a Prime designation from ISS ESG Rating, and inclusion in the Hang Seng Corporate Sustainability Benchmark Index.

About FTSE4Good Index Series

Created by the global index and data provider FTSE Russell, the FTSE4Good Index Series measures the performance of companies with strong Environmental, Social and Governance practices. The FTSE4Good indexes help a wide range of market participants build and evaluate responsible investment funds and other products.

FTSE Russell assessments focus on performance in areas such as Corporate Governance, Health and Safety, Anti-Corruption and Climate Change. Companies in the FTSE4Good Index Series satisfy various environmental, social and governance criteria.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) providing end-to-end solutions that enable partners to discover, develop and manufacture biologics from concept to commercialization for the benefit of patients worldwide.

With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore including experts and scientists in biologics research and development and manufacturing, technology innovation, and operational excellence WuXi Biologics applies its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to client needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company converts data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics supports 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics views sustainability as the foundation of long-term business growth. The company drives technology innovations to provide advanced end-to-end Green CRDMO solutions for its global partners while showing strong Environmental, Social and Governance practices. Committed to creating shared value, it works with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)

*The winner of the "2026 Best Contract Development and Manufacturing Organization Award" (ABEA)

Contacts

ESG
[email protected]

Media
[email protected]

SOURCE WuXi Biologics